期刊文献+

肺癌临床分期与C反应蛋白联合四项肿瘤标志物的相关性研究 被引量:5

下载PDF
导出
摘要 目的探讨C反应蛋白(CRP)联合4种血清肿瘤标志物[癌胚抗原(CEA)、糖类癌抗原125(CA125)、神经元特异性烯醇化酶(NSE)和细胞角蛋白19片段(CYFRA21-1)]与肺癌临床分期的相关性,并讨论其对肺癌辅助诊疗的临床价值。方法选择2016年1月到2017年11月广东医学院附属中山医院病理学或细胞学确诊的肺癌患者39例、同期医院肺部良性疾病患者43例、体检健康者43例,测定3组研究对象CRP及4项肿瘤标志物(CEA、CA125、NSE、CYFRA21-1)含量。结果肺癌组患者CRP值显著高于肺良性疾病组和体检健康组。Ⅰ/Ⅱ肺癌CRP值显著低于Ⅲ/Ⅳ肺癌CRP值,无转移肺癌CRP值显著低于有转移肺癌CRP值,差异具有统计学意义(P<0.05)。CPR联合4项肿瘤标志物灵敏度升高到88.1,特异度有所下降80.2,准确性达到82.1。结论 CPR联合4项肿瘤标志物在肺癌的辅助诊断中有着重要意义,可提高肺癌检测的灵敏度和准确度,肺癌患者CRP联合相关4项肿瘤标志物检测对肺癌分期和转移临床参考价值。
出处 《实用医技杂志》 2018年第4期380-382,共3页 Journal of Practical Medical Techniques
基金 广东省中山市医学科研项目(2016A020025)
  • 相关文献

参考文献2

二级参考文献52

  • 1Chen WQ Zhang SW, Zou XN. Evaluation on the incidence, mortality and tendency of lung cancer in China. Thoracic Cancer~ 2010, 1 (1): 35-40.
  • 2Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc, 2008, 83(5):584-594.
  • 3Mulshine JL, Sullivan DC. Clinical practice. Lung cancer screening. N Engl J Med, 2005, 353(20): 2194-2195.
  • 4Hatzakis KD, Froudarakis ME, Bouros D, et al. Prognostic value of serum tumor markers in patients with lung cancer. Respiration, 2002, 69(1): 25-29.
  • 5Greenberg AK, Lee MS. Biomarkers for lung cancer: clinical uses. Curr Opin Pulm Med, 2007, 13(4): 249-255.
  • 6Molina R, Auge JM, Filella X, et al. Pro-gastrin-releasing peptide (proGRP) in patients with benign, and malignant diseases: comparison with CEA, SCC, CYFRA 21-1, and NSE in patients with lung cancer. Anticancer Res, 2005, 25(3): 1773-1778.
  • 7Schneider J, Philipp M, Velcovsky HG, et al. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA), and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases. Anticancer Res, 2003, 23(2): 885-893.
  • 8Shibayama T, Ueoka H, Nishi K, et al. Complementary roles of pro-gastrinreleasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small cell lung cancer (SCLC). Lung Cancer, 2001, 32(1): 61-69.
  • 9Niho S, Nishiwaki Y, Goto K, et al. Significance of serum pro-gastrinreleasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuronspecific enolase and carcinoembryonic antigen. Lung Cancer, 2000, 27(3): 159-167.
  • 10Okusaka T, Eguchi K, Kasai T. Serum levels of Pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer. Clin Cancer Res, 1997, 3(1): 123-127.

共引文献83

同被引文献33

引证文献5

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部